Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Rhea-AI Summary

Esperion (NASDAQ: ESPR) has announced it will report fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before market opens. Management will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.

The company is a commercial stage biopharmaceutical firm that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) with allosteric mechanisms.

Positive

• FDA-approved oral medications in commercial stage
• Large-scale validation through 14,000 patient CLEAR trial
• Development of next-generation ACLYi program

Negative

• None.

ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025.

Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.

A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and esperionscience.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When will Esperion (ESPR) report Q4 and full year 2024 financial results?

Esperion will report Q4 and full year 2024 financial results before market opens on Tuesday, March 4, 2025.

What time is Esperion's (ESPR) Q4 2024 earnings webcast?

Esperion's Q4 2024 earnings webcast will be held at 8:00 a.m. ET on March 4, 2025.

How long will Esperion's (ESPR) Q4 2024 earnings webcast replay be available?

The webcast replay will be archived on Esperion's website for approximately 90 days.

What is Esperion's (ESPR) main commercial product focus?

Esperion commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C.

How many patients were involved in Esperion's (ESPR) CLEAR Cardiovascular Outcomes Trial?

The CLEAR Cardiovascular Outcomes Trial included nearly 14,000 patients.